Focus on GABAA receptor function
作者： H. Hautzel , S. Nikolaus , H.-W. Müller
DOI: 10.3413/NUKMED-0647-14-03
关键词:
摘要: Impairment of GABAA receptor function is increasingly recognized to play a major role in the pathophysiology neuropsychiatric diseases including anxiety disorder (AD), depressive (MDD) and schizophrenia (SZ). Patients, method: We conducted PUBMED search, which provided total 23 vivo investigations with PET SPECT, binding patients primary diagnosis AD (n = 14, 160 patients, 172 controls), MDD 2, 24 28 controls) or SZ 6, 77 90 was compared healthy individuals. Results: A retrospective analysis revealed that AD, differed as both site(s) extent(s) GABAergic impairment. Additionally, it may be stated that, while decline involved whole mesolimbocortical system, confined frontal temporal cortex. Conclusion: As GABA known inhibit dopamine serotonin, dysfunction associated disturbances dopaminergic serotonergic neurotransmission disorders.
thieme-connect.de 参考文章(55)
Suat Ying Tan Cherlyn, Puay San Woon, Jian Jun Liu, Wei Yi Ong, Guo Chuan Tsai, Kang Sim, Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: A decade of advance Neuroscience & Biobehavioral Reviews. ,vol. 34, pp. 958- 977 ,(2010) , 10.1016/J.NEUBIOREV.2010.01.002
Yoshiyuki Asai, Akihiro Takano, Hiroshi Ito, Yoshiro Okubo, Masato Matsuura, Akihiko Otsuka, Hidehiko Takahashi, Tomomichi Ando, Shigeo Ito, Ryosuke Arakawa, Kunihiko Asai, Tetsuya Suhara, GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for α5 subunit Schizophrenia Research. ,vol. 99, pp. 333- 340 ,(2008) , 10.1016/J.SCHRES.2007.10.014
W Kaschka, REDUCED BENZODIAZEPINE RECEPTOR BINDING IN PANIC DISORDERS MEASURED BY IOMAZENIL SPECT Journal of Psychiatric Research. ,vol. 29, pp. 427- 434 ,(1995) , 10.1016/0022-3956(95)00019-2
Kelly A. Newell, Katerina Zavitsanou, Stephen Kum Jew, Xu-Feng Huang, Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry. ,vol. 31, pp. 225- 233 ,(2007) , 10.1016/J.PNPBP.2006.07.004
Anthony A. Grace, Benjamin S. Bunney, Paradoxical GABA excitation of nigral dopaminergic cells: Indirect mediation through reticulata inhibitory neurons European Journal of Pharmacology. ,vol. 59, pp. 211- 218 ,(1979) , 10.1016/0014-2999(79)90283-8
Susanne Graef, Peter Schönknecht, Osama Sabri, Ulrich Hegerl, None, Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. Psychopharmacology. ,vol. 215, pp. 205- 229 ,(2011) , 10.1007/S00213-010-2153-8
Christine Konradi, Stephan Heckers, Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment Pharmacology & Therapeutics. ,vol. 97, pp. 153- 179 ,(2003) , 10.1016/S0163-7258(02)00328-5
Susanne Nikolaus, Christina Antke, Hans-Wilhelm Müller, In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders Behavioural Brain Research. ,vol. 204, pp. 32- 66 ,(2009) , 10.1016/J.BBR.2009.06.009
J.Douglas Bremner, Robert B Innis, Thomas White, Masahiro Fujita, David Silbersweig, Andrew W Goddard, Lawrence Staib, Emily Stern, Angela Cappiello, Scott Woods, Ronald Baldwin, Dennis S Charney, SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder Biological Psychiatry. ,vol. 47, pp. 96- 106 ,(2000) , 10.1016/S0006-3223(99)00188-2
Mihaly Hajos, Bruce Rogers, Targeting α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia Current Pharmaceutical Design. ,vol. 16, pp. 538- 554 ,(2009) , 10.2174/138161210790361434